IP Library › Patent Application 19084026
Patent Application
App. No. 19/084,026

METHOD OF ENHANCING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
19/084,026
Abstract

Methods of preferentially enhancing in a subject an antibody-dependent cell-mediated cytotoxicity (ADCC) antibody response over a neutralizing antibody response to a vaccine for an infectious agent using herpesvirus entry mediator (HVEM) agonists, and related compositions.

Claims (38)

1 . (canceled)

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . (canceled)

8 . (canceled)

9 . (canceled)

10 . (canceled)

11 . (canceled)

12 . (canceled)

13 . (canceled)

14 . (canceled)

15 . (canceled)

16 . (canceled)

17 . (canceled)

18 . (canceled)

19 . (canceled)

20 . (canceled)

21 . (canceled)

22 . (canceled)

23 . (canceled)

24 . (canceled)

25 . (canceled)

26 . (canceled)

27 . (canceled)

28 . (canceled)

29 . (canceled)

30 . A method of decreasing or blocking Fc-gamma receptor (FcγR)-mediated killing of self-antigen in a subject having an autoimmune disease comprising administering to the subject an amount of an HVEM antagonist, a soluble herpes simplex virus (HSV) glycoprotein D, an antibody binding HVEM, or a combination thereof, effective to decrease or block the FcγR-mediated killing in the subject.

31 . A method of blocking Fc-gamma receptor (FcγR)-mediated killing of self-antigen in a subject having an autoimmune disease comprising administering to the subject an amount of an HVEM antagonist, a soluble herpes simplex virus (HSV) glycoprotein D, an antibody binding HVEM, or a combination thereof, effective to reduce the autoimmune disease in the subject.

32 . The method of claim 30 , wherein the soluble HSV glycoprotein D comprises HSV-1 glycoprotein D, HSV-2 glycoprotein D, or a combination thereof.

33 . The method of claim 31 , wherein the soluble HSV glycoprotein D comprises HSV-1 glycoprotein, HSV-2 glycoprotein D, or a combination thereof.

30 . The method of claim 30 , wherein the HVEM antagonist binds HVEM.

35 . The method of claim 31 , wherein the HVEM antagonist binds HVEM.

36 . A kit for decreasing or blocking Fc-gamma receptor (FcγR)-mediated killing of self-antigen in a subject having an autoimmune disease comprising an HVEM antagonist, a soluble HSV glycoprotein D, an antibody binding HVEM, or a combination thereof.

37 . The kit according to claim 36 , wherein the soluble glycoprotein D comprises HSV-2 glycoprotein D, HSV-2 glycoprotein D, or a combination thereof.

38 . The kit according to claim 36 , wherein the HVEM antagonist binds HVEM.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2025
From: HEROLD, BETSY; BURN, CLARE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 070561/0022 →